Understanding EMPLICITI®

Empliciti® (elotuzumab) is the first immunostimulatory monoclonal antibody approved for the treatment of myeloma. Empliciti enlists immune system cells to attack myeloma. Before reading this booklet, it may be helpful to read another IMF publication, Understanding the Immune System in Myeloma.



Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.